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Summary
Objective. To screen a cohort of patients diagnosed with non-FXII an-
gioedema for carriage of variants of F12 gene.
Material and methods. DNA samples from 191 patients suffering 
from primary angioedema with normal C1-INH, 54 samples from non-
-affected family members, and 161 samples from C1-INH-HAE (154 
type I, 7 type II) patients were included in the study. The F12 gene was 
genotyped by targeted NGS (100% coverage of translated regions). 
Sanger sequencing was performed for the verification of all identified 
variants and family segregation studies.
Results. The pathogenic F12 variant c.983C>A was detected in three 
patients from two unrelated families initially diagnosed as U-HAE. Six 
additional mutations were identified, four of which were characteri-
zed as benign (c.41T>C, c.418C>G, c.1025C>T, c.530C>T) and two 
of uncertain significance (c.1530G>C, c.1768T>G). Two synonymo-
us variants (c.756C>T and c.711C>T), the common polymorphism 
c.619G>C, and the functional polymorphism c.-4T>C were detected 
in allele frequencies similar to those presented in the ExAC database 
for the European population. One more not yet reported synonymous 
variant (c. 1599A>G) was also found.
Conclusion. Analyzing the entire translated region of F12 gene is 
important in order to identify new variants that possibly affect HAE 
expressivity. Interestingly, genetic analysis of F12 supports not only 
the diagnosis of FXII-HAE but also the correct exclusion diagnosis of 
U-HAE.
Keywords: F12 gene, F12 mutations, hereditary angioedema, next-ge-
neration sequencing
Streszczenie
Cel. Przesiewowe badanie kohorty pacjentów z rozpoznanym obrzę-
kiem naczynioruchowym innym niż zależny od FXII w kierunku nosi-
cielstwa wariantów genu F12.
Materiał i metody. Do badania włączono próbki DNA 191 pacjentów cier-
piących na pierwotny obrzęk naczynioruchowy z prawidłowym C1-INH, 
54 zdrowych członków rodzin oraz 161 pacjentów z C1-INH-HAE 
(154 typ I, 7 typ II). Gen F12 był genotypowany metodą NGS (obejmu-
jącą cały rejon poddany translacji). Sekwencjonowanie metodą Sange-
ra zostało wykonane celem weryfikacji wszystkich zidentyfikowanych 
wariantów i badań segregacyjnych rodzin.
Wyniki. U trzech pacjentów z dwóch niespokrewnionych rodzin pier-
wotnie zdiagnozowanych jako U-HAE wykryto patogenny wariant F12: 
c.983C>A. Zidentyfikowano sześć dodatkowych mutacji, z których 
cztery zostały określone jako łagodne (c.41T>C, c.418C>G, c.1025C>T, 
c.530C>T), a dwie jako mutacje o niepewnym znaczeniu (c.1530G>C, 
c.1768T>G). Stwierdzono dwa warianty synonimiczne (c.756C>T oraz 
c.711C>T), pospolity polimorfizm (c.619G>C) oraz czynnościowy 
polimorfizm c.-4T>C z częstością alleliczną podobną do podawanej 
w bazie ExAC dla populacji europejskiej. Wykryto również jeden nie 
raportowany dotychczas wariant synonimiczny (c. 1599A>G).
Wnioski. Analiza całego rejonu genu F12 poddawanego translacji jest 
ważna dla identyfikowania nowych wariantów, które mogą oddziały-
wać na ekspresję HAE. Ponadto, analiza genetyczna F12 pozwala nie 
tylko na potwierdzenie rozpoznania FXII-HAE, ale również prawidłowe 
wykluczenie rozpoznania U-HAE.
Słowa kluczowe: gen F12, mutacje F12, wrodzony obrzęk naczynio-
ruchowy, sekwencjonowanie następnej generacji
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INTRODUCTION
HAE is a rare and potentially life-threatening genetic dis-
order, manifested by recurrent attacks of subcutaneous and/
or submucosal edemas which develop as a result of tran-
sient release of vasoactive peptides and increased permea-
bility of blood vessels [1]. Its pathogenicity, until now, has 
been associated with mutations in four genes, SERPING1 
[1], F12 [1], PLG [2, 3] and ANGPT1 [4]. Mutations in SERP-
ING1 result in deficiencies of C1-INH causing C1-INH-HAE, 
whereas the other mutations do not affect concentration or 
function of C1-INH. These types of HAE are called nC1-INH-
HAE, regardless if a mutation is known (FXII-HAE, PLG-HAE, 
ANGPT1-HAE) or not (U-HAE). The conventional analysis of 
these genes is cumbersome, time consuming, and unable 
to support parallel investigation of multiple targets. Recent 
progress in massive parallel sequencing, termed NGS, has 
increased the speed and efficiency of mutation testing. As 
NGS overcomes many of the obstacles that have been faced 
by traditional approaches, we proceeded to the develop-
ment and validation of a custom NGS platform (NGS-HAE 
panel) that targets the entire 11q12-q13.1 locus, includ-
ing the promoter, coding, intron-exon boundary, intronic 
regions of the SERPING1 gene [5]. Aiming to examine the 
possible involvement of other genes in the manifestation of 
HAE, we expanded this panel by introducing a number of 
genes encoding for proteins involved in bradykinin metab-
olism and function, including F12.
As it is known, four F12 pathogenic alterations have been 
identified, so far: two missense mutations (c.983C>A and 
c.983C>G) [6], a deletion of 72 bp (c.971_1018+ 24del72) 
[7] and a duplication of 18 bp (c.892_909dup) [8]. Further-
more, the functional promoter polymorphism F12 c.-4T>C 
(rs1801020) acts as an independent modifier of C1-INH-
HAE severity [9]. Finally, in a recent study a patient bearing 
two co-existing pathogenic mutations in SERPING1 and F12 
gene has been described [10].
The aim of this article is to present the data obtained 
from genotyping a cohort of patients with different types 
of angioedema using the above mentioned NGS-HAE pan-
el, as far as, the F12 gene is regarded.
Abbreviations:
ACEi-AAE ‒ acquired angioedema related to angioten-
sin-converting enzyme inhibitor
C1-INH ‒ C1-inhibitor
C1-INH-HAE ‒ hereditary angioedema due to C1-INH de-
ficiency
FXII-HAE ‒ hereditary angioedema with F12 mutation
HAE ‒ hereditary angioedema
INH-AAE ‒ idiopathic non-histaminergic acquired an-
gioedema
ISPs ‒ enriched template-positive Ion Sphere Particles
n-C1-INH-HAE ‒ hereditary angioedema with normal 
C1-esterase inhibitor
NGS ‒ next generation sequencing
PGM ‒ personal genome machine
U-HAE ‒ unknown hereditary angioedema
VUS ‒ variant of uncertain significance
MATERIAL AND METHODS
Study subjects
A total of 191 DNA samples with normal C1-inhibi-
tor (139 U-HAE, 14 INH-AAE, 3 ACEi-AAE, 8 CPN1 de-
ficiency, 27 samples from patients with recurrent an-
gioedema and normal C1-INH but with unknown 
family history and not fulfilling the criteria for INH-
AAE) belonging to 160 families of European origin 
(52 Hungarian, 33 Greek, 3 German, 28 Spanish, 8 Polish, 
31 Italian, 3 French, 2 Bulgarian) were genotyped along 
with 54 samples from non-affected family members. Ad-
ditionally, 161 C1-INH-HAE (154 type I, 7 type II) samples 
bearing various SERPING1 pathogenic mutations were 
screened for the presence of a mutation in F12 gene. The 
local institutional review boards approved this study, and 
written informed consent was obtained from each individ-
ual or an accompanying relative.
Next-Generation Sequencing
A NGS custom panel was designed using the Ion AmpliS-
eq Thermo Fisher Scientific Designer, in order to analyze all 
the exonic, exon-intron junctions and untranslated (5’ and 
3’-UTR) regions of the F12 gene. 16 amplicons divided in 
two primer pools provide 100% coverage of all translated 
regions of the gene. Additional amplicons (809 in total) for 
different genes (n=55) selected among those encoding for 
proteins involved in bradykinin metabolism, including SER-
PING1 gene, were introduced to the panel. Amplicon librar-
ies of the F12 regions were prepared using an Ion AmpliSeq 
Library Kit 2.0 (Thermo Scientific) and Ion Xpress™ Barcode 
Adapter 1-96 Kit (Thermo Scientific). Pooled, barcoded li-
braries were clonally amplified using the Ion OneTouch™ 
system and Ion OT2 HI-Q Template kit (Thermo Scientific). 
ISPs were enriched with the Dynabeads® MyOne™ Streptavi-
din C1 Beads (Thermo Scientific) and washed with the Ion 
OneTouch Wash Solution included in the kit using the Ion 
One Touch ES system (Thermo Scientific). The subsequently 
enriched template-positive ISPs were loaded onto Ion 318 
chips and sequenced on the PGM using the Ion PGM Hi-Q 
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sequencing kit (Thermo Scientific). All procedures were per-
formed according to the manufacturer’s instructions.
Sequencing raw data were analyzed for base calling, 
demultiplexing, alignment to hg19 reference genome 
(GRCh37), coverage analysis and variant calling on Torrent 
Suite 5.2 software (Ion Torrent) using default parameters. 
The plugins used for the analysis were CoverageAnalysis 
v.5.2.1.2 and VariantCaller v.5.2. The reference sequenc-
es of F12 and SERPING1 genes were NM_000505.3 and 
NM_000062.2, respectively. Annotation of variants was 
performed on Ion Reporter software v.5.2 (Thermo Scientif-
ic). PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) and 
SIFT (http://sift.jcvi.org/) bioinformatic tools were used to 
predict the effect of amino acid substitution. The integra-
tive genomics viewer v2.2 (IGV, Broad Institute) was used 
for visualization.
Sanger sequencing was performed for the verification 
of all identified variants and family segregation studies, as 
previously described [11].
RESULTS
All variants detected in the F12 gene are presented in 
Figure 1, while their allele frequencies are shown in Table I.
The missense pathogenic mutation c.983C>A (p.Thr-
328Lys, rs118204456) of the F12 gene was identified in 
three subjects, belonging to two unrelated Spanish fami-
lies, initially diagnosed with U-HAE.
Beyond this, six F12 missense mutations were found in 
our patients (Fig. 1). In two different patients with type I C1-
INH-HAE the mutations c.41T>C (p.Leu14Ser, rs143809932) 
and c.1025C>T (p.Pro342Leu, rs2230939) were detected. 
The mutation c.418C>G (p.Leu140Val, rs35515200) was 
detected in one German patient with type I C1-INH-HAE 
and in two patients with U-HAE, one of Italian and the oth-
er of Polish origin. The mutation c.530C>T (p.Ala177Val, 
rs144821595) was detected in two U-HAE patients, while 
the c.1768T>G (p.Cys590Gly) and the c.1530G>C (p.Glu-
510Asp) were detected in two different patients with nor-
mal C1-INH.
Carriers of combined SERPING1 and F12 pathogenic mu-
tations were not detected.
Two common synonymous mutations were identified 
(c.756C>T, rs41309752 and c.711C>T, rs17876047) and 
their allele frequencies in individuals of European origin are 
0.97% and 4.02% respectively (ExAC database). Additional-
ly, one rare synonymous mutation (c.1599A>G), not pub-
lished in NCBI and ExAC databases, was detected in a single 
U-HAE patient of Hungarian origin. 
Finally, the common F12 polymorphism rs17876030 
(c.619G>C, p.Ala207Pro, exon 7) was detected in 11 sam-
ples (5 C1-INH-HAE, 6 nC1-INH-HAE) while the functional 
promoter polymorphism F12 c.-4T>C (rs1801020) was de-
tected in 73 samples (13 homozygous) with normal C1-INH 
belonging to 60 families and 52 samples with C1-INH-HAE 
(9 homozygous).
DISCUSSION
Approximately 25% of angioedema cases with normal 
C1-INH are associated with a mutation in the F12 gene 
[12]. The mutations described until now as causative for 
FXII-HAE are located in exon 9 of the F12 gene. The majority 
of patients bear the c.983C>A substitution which results 
in a threonine-to-lysine aminoacid change (p.Thr328Lys) 
in factor XII [12]. Another mutation predicting a threo-
nine-to-arginine substitution (c.983C>G, p.Thr328Arg) in 
the same codon has been described in two German families 
[6]. There has also been a report of an 18-bp duplication 
(c.892_909dup) in a Hungarian family and a 72-bp deletion 
(c.971_1018 + 24del72) in a Turkish family [7, 8]. All these 
F12 alteration Allele frequencies





utr_5 Functional Polymorphism c.-4T>C 24.02% 60 (22.81%) 52 (18.94%)
Exon 1 Likely Benign c.41T>C 0.01% 0 (<0.001%) 1 (0.31%)
Exon 6 Benign c.418C>G 0.32% 2 (0.62%) 1 (0.31%)
Exon 7 Benign c.530C>T 0.01% 2 (0.62%) 0 (<0.001%)
Exon 7 Polymorphism c.619G>C 1.38% 6 (2.5%) 5 (1.55%)
Exon 8 Synonymous c.711C>T 4.02% 8 (2.5%) 6 (1.86%)
Exon 8 Synonymous c.756C>T 0.97% 4 (1.25%) 5 (1.55%)
Exon 9 Pathogenic c.983C>A <0.001% 2 (0.62%) 0 (<0.001%)
Exon 10 Benign c.1025C>T 0.11% 0 (<0.001%) 1 (0.31%)
Exon 12 VUS c.1530G>C <0.001% 1 (0.31%) 0 (<0.001%)
Exon 13 Synonymous c.1599A>G <0.001% 1 (0.31%) 0 (<0.001%)
Exon 14 VUS c.1768T>G <0.001% 1 (0.31%) 0 (<0.001%)
Table I. The allele frequencies of all mutations
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mutations are located in the proline-rich linker peptide be-
tween the Kringle and trypsin-like serine protease (Tryp-SPc) 
domains of the FXII protein.
The mechanism of function of FXII-HAE is not fully un-
derstood. It has been proposed that the p.Thr328Lys in-
creases enzymatic plasma activity in female mutation car-
riers that leads to enhanced kinin production resulting in 
angioedema [13]. Contrary to this study, Bork et al. have 
shown that there is no difference between FXII-HAE pa-
tients bearing the p.Thr328Lys mutation and their healthy 
probands in regard to FXII surface activation concluding 
that the mutation does not cause a ‘gain-of-function’ of 
FXIIa [14]. Subsequent in vivo and in vitro experiments in 
mice suggest that p.Thr328Lys and p.Thr328Arg result to 
the loss of O-linked glycosylation [15]. As a result, the pro-
line-rich region is less negatively charged and the overall 
protein size of the mutant FXII molecule is reduced caus-
ing an increase in the susceptibility of FXII zymogen auto-
activation that leads to excessive activation of bradykinin 
formation through the kallikrein-kinin pathway [16]. Fur-
thermore, these mutations lead in accelerated activation of 
the FXII by a plasmin, a natural activator of contact system 
[17]. However, further investigation is necessary to deter-
mine the pathway by which these alterations contribute to 
the formation of hereditary angioedema.
In this study, the mutation c.983C>A was identified in 
three women from two unrelated Spanish families initially 
misdiagnosed as U-HAE. These patients demonstrate fea-
tures indicative of FXII-HAE in that attacks were appeared 
either during gestational periods or after the administration 
of estrogens.
Additionally, we identified six rare or not yet reported 
mutations in the F12 gene (c.41T>C, c.418C>G, c.530C>T, 
c.1025C>T, c.1530G>C, c.1768T>G). The mutation 
c.41T>C (p.Leu14Ser), located in exon 1 of the F12 gene, 
was identified in a single type I C1-INH-HAE Bulgarian pa-
tient co-carrying a pathogenic frameshift mutation in SER-
PING1 gene. This variant is predicted to be deleterious by 
SIFT and probably damaging by PolyPhen2 analysis. Un-
fortunately, family segregation was impossible. Neverthe-
less, considering that the mutation has been detected in 
0.01507% individuals of European origin (ExAC database) 
Fig. 1. Detected mutations in the F12 gene
Fig. 2. Family segregation study for the c.1530G>C (p.Glu510Asp) in the F12 gene
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and that its allele frequency is greater than that expected 
for FXII-HAE and F12 deficiency, according to ACMG guide-
lines it is interpreted as likely benign [18].
The c.418C>G (p.Leu140Val) mutation is located in 
exon 6 of the F12 gene and was detected in one German 
patient with type I C1-INH-HAE and two (an Italian and 
a Polish) U-HAE patients. Bioinformatic analysis by SIFT and 
PolyPhen2 algorithms predicted this mutation as tolerated 
and possibly damaging, respectively. The mutation is char-
acterized as likely benign in ClinVar database in association 
to hereditary angioedema and factor XII deficiency. It has 
been detected in 0.3283% individuals of European origin 
and 0.2215% worldwide. Family segregation study per-
formed in the two families of U-HAE revealed the mutation 
in three healthy family members, a fact supporting its pre-
vious characterization as benign.
The alteration c.530C>T (p.Ala177Val) is located in exon 
7 of the F12 gene and was detected in one Spanish and one 
Italian U-HAE patient. It presents with an allele frequency of 
0.01413% and 0.00907% (ExAC database) in the European 
and worldwide population, respectively, and is predicted to 
be benign by both SIFT and PolyPhen2 bioinformatic tools. 
Family segregation in the Italian family supported that this 
alteration is benign for FXII-HAE, as three healthy members 
of the family were also carriers of the mutation.
Another alteration (c.1025C>T, p.Pro342Leu), was de-
tected in exon 10 of the F12 gene in one type I C1-INH-HAE 
Polish patient bearing a pathogenic SERPING1 mutation. 
c.1025C>T is reported as likely benign in ClinVar database 
(rs2230939) in patients with HAE and FXII deficiency. This 
mutation is detected in 0.1804% individuals of European 
origin and was predicted to be benign by both SIFT and 
PolyPhen2 bioinformatic tools. Our data support the previ-
ous characterization of the mutation as benign.
The alteration c.1530G>C (p.Glu510Asp) was identified 
in a 12-year old girl with hereditary angioedema present-
ing with five to six angioedema attacks per month located 
in the face. This mutation was predicted as probably dam-
aging by both the bioinformatic tools used in this study 
(SIFT and PolyPhen2). There is no report of this mutation in 
ClinVar database and it is not detected amongst 115000 ex-
omes of the ExAC database. Family segregation study iden-
tified the mutation in the father of the patient, who had 
no angioedema attacks during his life (Figure 2). However, 
FXII-HAE has a very low penetrance, particularly in males 
(over 90% of male carriers are asymptomatic compared 
with 40% of females) [19]. This substitution occurs at the 
catalytic domain of the FXII protein. As the available evi-
dence is currently insufficient to determine the role of this 
variant in FXII-HAE, we classify this mutation as a variant of 
uncertain significance (VUS). Nevertheless, it would be very 
interesting to test female probands of the patient’s father, 
if any, in order to clarify its pathogenicity.
In one German patient the mutation c.1768T>G (p.Cys-
590Gly) in exon 14 of the F12 gene was detected. The pa-
tient is presenting with recurrent angioedema of unclear 
origin. c.1768T>G is predicted deleterious by SIFT and pos-
sibly damaging by PolyPhen2 analysis. There is no report 
of this mutation in ClinVar database and is not detected 
amongst 115000 exomes of the ExAC database. The sub-
stitution occurs at the catalytic domain of the FXII protein 
and in the same nucleotide position a substitution has been 
described (c.1768T>A, p.Cys590Ser, rs1157280571) lead-
ing to loss of enzyme activity [20]. However, it is currently 
unclear if c.1768T>G is a pathogenic variant and thus it is 
characterized as a VUS for FXII-HAE.
The allele frequencies of all common polymorphisms 
(rs17876030, rs41309752 and rs17876047 and rs1801020) 
are similar with the corresponding allele frequencies pre-
sented in the ExAC database for the European population 
(Table I). The rare (c.1599A>G) synonymous variant, ac-
cording to Human Splicing Finder 3 bionformatic tool, is 
not predicted to have an effect in the splicing of the tran-
script.
It is concluded that high-throughput genomic technol-
ogies facilitate an extended analysis of genes involved in 
the pathogenesis of angioedema. However, the interpreta-
tion of their results represents a rather challenging attempt. 
In many genes, including SERPING1, a loss of function is 
a known disease mechanism and clearly deleterious vari-
ants (nonsense, frameshift, indels, splice defects) can be 
considered pathogenic. In F12 gene, however, only specific 
variants lead to FXII-HAE, as causative variants must induce 
a gain of function in the encoded protein. This applies in mis-
sense or synonymous F12 variants posing great challenges 
to interpretation. Loss of function variants in the gene are 
associated with Factor XII deficiency (OMIM: 234000), and 
thus are not expected to be identified in FXII-HAE patients. 
Furthermore, F12 variants have been shown to have low 
penetrance, particularly in males, adding another level of 
difficulty. In the absence of functional and conclusive family 
segregation studies all missense variants, predicted to mod-
ify the structure of the protein and located outside exon 
9 are characterized as VUS.
References
  1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and 
approach to treatment for angioedema: consensus report from 
the Hereditary Angioedema International Working Group. Allergy 
2014; 69: 602-16.
  2. Dewald G. A missense mutation in the plasminogen gene, within 
the plasminogen kringle 3 domain, in hereditary angioedema with 
normal C1 inhibitor. Biochem Biophys Res Commun 2018; 498: 
193-8.
  3. Bork K, Wulff K, Steinmüller-Magin L, et al. Hereditary angioedema 
with a mutation in the plasminogen gene. Allergy 2018; 73: 442-
50.
  4. Bafunno V, Firinu D, D'Apolito M, et al. Mutation of the angio-po-
ietin-1 gene (ANGPT1) associates with a new type of hereditary an-
gioedema. J Allergy Clin Immunol 2018; 141: 1009-17.
  5. Loules G, Zamanakou M, Parsopoulou F, et al. Targeted next-gene-
ration sequencing for the molecular diagnosis of hereditary angio-
edema due to C1-inhibitor deficiency. Gene 2018; 667: 76-82.
  6. Bork K. Hereditary angioedema with normal C1 inhibitor activity 
including hereditary angioedema with coagulation factor XII gene 
mutations. Immunol Allergy Clin North Am 2006; 6: 709-24.
  7. Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation 
factor 12 gene in subjects with hereditary angioedema and normal 
C1-inhibitor. Clin Immunol 2011; 141: 31-5.
  8. Kiss N, Barabás E, Várnai K, et al. Novel duplication in the F12 gene 
in a patient with recurrent angioedema. Clin Immunol 2013; 149: 
142-5.
210 Alergia Astma Immunologia 2018, 23 (4): 205-210
  9. Speletas M, Szilágyi Á, Csuka D, et al. F12-46C/T polymorphism as 
modifier of the clinical phenotype of hereditary angioedema. Aller-
gy 2015; 70: 1661-4.
10. Charignon D, Ponard D, de Gennes C, et al. SERPING1 and F12 
combined variants in a hereditary angioedema family. Ann Allergy 
Asthma Immunol 2018; 121: 500-2.
11. Singhamatr P, Kanjanapongkul S, Rojnuckarin P. Molecular analysis 
of factor XII gene in Thai patients with factor XII deficiency. Blood 
Coagul Fibrinolysis 2013; 24: 599-604.
12. Dewald G, Bork K. Missense mutations in the coagulation factor XII 
(Hageman factor) gene in hereditary angioedema with normal C1 
inhibitor. Biochem Biophys Res Commun 2006; 43: 1286-9.
13. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagu-
lation factor XII (Hageman factor) causes hereditary angioedema 
type III. Am J Hum Genet 2006; 79: 1098-104.
14. Bork K, Kleist R, Hardt J, et al. Kallikrein - kinin system and fibri-
nolysis in hereditary angioedema due to factor XII gene mutation 
Thr309Lys. Blood Coagul Fibrinolysis 2009; 20: 325-32.
15. Björkqvist J, de Maat S, Lewandrowski U, et al. Defective glycosyla-
tion of coagulation factor XII underlies hereditary angioedema type 
III. J Clin Invest 2015; 125: 3132-46.
16. Magerl M, Germenis AE, Maas C, Maurer M. Hereditary Angioede-
ma with Normal C1 Inhibitor: Update on Evaluation and Treatment. 
Immunol Allergy Clin North Am 2017; 37: 571-84.
17. de Maat S, Björkqvist J, Suffritti C, et al. Plasmin is a natural trigger 
for bradykinin production in patients with hereditary angioedema 
with factor XII mutations. J Allergy Clin Immunol 2016; 138: 1414-
23.e9.
18. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assuran-
ce Committee. Standards and guidelines for the interpretation of 
sequence variants: a joint consensus recommendation of the Ame-
rican College of Medical Genetics and Genomics and the Associa-
tion for Molecular Pathology. Genet Med 2015;17: 405-24.
19. Caballero T, Canabal J, Rivero Paparoni D, et al. Management of he-
reditary angioedema in pregnant women: a review. Int J Womens 
Health 2014; 9: 839-48.
20. Miyata T, Kawabata S, Iwanaga S, et al. Coagulation factor XII (Ha-
geman factor) Washington D.C.: inactive factor XIIa results from 
Cys-571-Ser substitution. Proc Natl Acad Sci U S A 1989; 86: 8319-
22.
